The pharmacokinetic and pharmacodynamic properties of vancomycin.
about
Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-AnalysisDose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsOptimizing the Clinical Use of VancomycinBenefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysisEvaluation of treatment with Oseltamivir during the 2009 H1N1 (swine flu) pandemic: the problem of incomplete clinical information.The Mark Coventry Award: Higher tissue concentrations of vancomycin with low-dose intraosseous regional versus systemic prophylaxis in TKA: a randomized trialPreclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal functionSerum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.Vancomycin revisited - 60 years laterBorrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.Vancomycin displays time-dependent eradication of mature Staphylococcus aureus biofilms.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patientsAchieving therapeutic vancomycin levels in pediatric patientsVancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.Current and novel antibiotics against resistant Gram-positive bacteriaRefining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.Heparinized nanohydroxyapatite/collagen granules for controlled release of vancomycin.Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.In vivo pharmacodynamic activity of the glycopeptide dalbavancinVancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?Vancomycin Use in Patients Discharged From the Emergency Department: A Retrospective Observational Cohort StudyProphylactic Vancomycin Drops Reduce the Severity of Early Bacterial Keratitis in Keratoprosthesis.Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery.Local Intramedullary Delivery of Vancomycin Can Prevent the Development of Long Bone Staphylococcus aureus Infection.Regional Intraosseous Administration of Prophylactic Antibiotics is More Effective Than Systemic Administration in a Mouse Model of TKA.Clinical Pharmacology Studies in Critically Ill Children.Factors impacting unbound vancomycin concentrations in different patient populations.Immunocytochemistry for vancomycin using a monoclonal antibody that reveals accumulation of the drug in rat kidney and liverPerformance of cystatin C- and creatinine-based estimated glomerular filtration rate equations depends on patient characteristics.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.Vancomycin treatment and butyrate supplementation modulate gut microbe composition and severity of neointimal hyperplasia after arterial injury.Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.
P2860
Q26770913-5990538C-2B39-4E74-9F4C-F2D2D5C28621Q26853629-EA924E7C-897D-4FA6-9AEE-580EF9AB2BE0Q28069334-99DDBEFD-1B70-4C10-A0E5-8B701FCD4536Q28534516-B0C3446F-435A-4AC7-8A37-27AAB9A0833AQ30418763-A271506F-1265-4053-B099-B1199C78BFF1Q30564105-EC9120A8-3079-44C3-94D8-389FB5D7EF64Q33586699-7EA113EA-1061-4957-9DFA-5C510B5ED2C7Q33613764-693DB715-32B2-42E7-9ABE-6E91E43F1C11Q33821959-77AA50BF-53F3-42D6-A4C6-472159D65CF8Q33949459-DE09E955-E3E1-45D6-9673-E5C50099C975Q34433066-9687D5D2-2A65-45AE-A57B-0B4B79F22C25Q34478025-18C37D79-A9B1-4E35-A620-1CD476A3BCF5Q34526414-003359C6-542D-4CF6-9F53-5B361D1054EDQ34573702-421EE853-505C-4DB5-8C71-78EE9083A2ADQ34764337-BFAF13C9-8459-4655-98EC-9101C57EEC6BQ35004943-69C7F3C2-8835-4C7D-8A7D-FC29CC1626A6Q35026521-4BD5BB2D-8434-4220-B09F-F07987509AEAQ35191519-463F6550-0063-413F-A598-6E41E0918454Q35578972-79A8073C-7C55-469C-BC70-3157DA719350Q35598479-2A068DD7-2E9C-4101-B054-516BB666BB2AQ35759076-F42033B0-01D0-41DA-A0EE-6B0D27A50654Q35763971-ABA313F3-86C6-4AF2-ACBF-2E6AE0568326Q35768102-2B742498-36A3-4F77-BD87-EAC2F94CDA57Q35804533-0E88721D-C886-43E9-AF73-49E9E68BAD93Q35905561-A5E0BA59-5B6F-4411-A032-3EF1DD093C1DQ36025950-4C1E9A6E-08AE-4653-AA44-F1886BB8FE27Q36089510-444B1B13-D75A-4EE2-BC12-5D36F05956B0Q36100961-69BAC4C4-91C8-4E31-9A7A-2FD8C0ACA8F3Q36120465-11A65791-D8DB-4FB8-AA84-E63F221F1435Q36158421-6FECD722-B2AA-4CBD-B978-69639D58E87CQ36364137-4FBCCAB3-A7D8-4F63-A1F4-3A3D6BBDCF8AQ36501261-2EA52DB4-CEAC-4B89-8DED-A53CCF2AE76EQ36505518-61D0A227-7073-4BDF-AF94-45D81E9B7025Q36571794-94D2CFED-D7EF-4A80-9DD3-F05CBF4AB224Q36597901-E32A5B31-91D4-42F3-B8C8-18B31AF4A65DQ36666985-611AB0FE-DF4F-4564-B376-14659ED37728Q36718474-AE4D8E15-0EBE-4081-ADDD-3B0633DE32BEQ36748977-9F68AA37-CE35-4B49-A86C-674C42A12CADQ36757645-18F4648B-9CA2-4439-8CC0-77BDAD6AC983Q36777850-FEAA2D31-73F1-44FE-B008-327EF0BF5AD5
P2860
The pharmacokinetic and pharmacodynamic properties of vancomycin.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@ast
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@en
type
label
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@ast
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@en
prefLabel
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@ast
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@en
P2860
P356
P1476
The pharmacokinetic and pharmacodynamic properties of vancomycin.
@en
P2093
Michael J Rybak
P2860
P356
10.1086/491712
P407
P478
42 Suppl 1
P577
2006-01-01T00:00:00Z